Department of Internal Medicine, Division of Infectious Diseases, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
Department of Medical Microbiology, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105, AZ, Amsterdam, The Netherlands.
BMC Infect Dis. 2021 Mar 20;21(1):285. doi: 10.1186/s12879-021-05919-w.
The systemic response to an infection might influence the pharmacokinetics of antibiotics. To evaluate the desired possibility of an earlier (< 24 h) IV-to-oral switch therapy in febrile non-ICU, hospitalized patients, a systematic review was performed to assess the effect of the initial phase of a systemic infection on the bioavailability of orally administered antibiotics in such patients.
An electronic search was conducted in MEDLINE and Embase up to July 2020. Studies were selected when outcome data were collected during the initial stage of a febrile disease. Outcome data were (maximum) serum concentrations, time of achieving maximum serum concentration, and the area-under-the-plasma-concentration-time curve or bioavailability of orally administered antibiotics. Risk of bias was assessed.
We identified 9 studies on 6 antibiotics. Ciprofloxacin was the most frequently studied drug. Outcomes of the studies were heterogeneous and generally had a high risk of bias. Three small studies, two on ciprofloxacin and one on clarithromycin, compared the pharmacokinetics of febrile patients with those of clinically recovered patients and suggested that bioavailability was not altered in these patients. Other studies either compared the pharmacokinetics in febrile patients with reported pharmacokinetic values from earlier studies in healthy volunteers (n = 2), or provided no comparison at all and were non-conclusive (n = 4).
There is a clear knowledge gap regarding the bioavailability of orally administered antibiotics in non-ICU patients during the initial phase of a systemic infection. Well-designed studies on this topic are necessary to elucidate whether patients can benefit from the advantages of an earlier IV-to-oral switch.
感染的全身反应可能会影响抗生素的药代动力学。为了评估非 ICU 住院发热患者更早(<24 小时)进行静脉-口服转换治疗的可能性,我们进行了一项系统评价,以评估全身感染初始阶段对这些患者口服抗生素生物利用度的影响。
我们在 MEDLINE 和 Embase 上进行了电子检索,检索截至 2020 年 7 月。当在发热疾病的初始阶段收集结局数据时,我们选择了研究。结局数据为(最大)血清浓度、达到最大血清浓度的时间以及口服抗生素的血药浓度-时间曲线下面积或生物利用度。评估了偏倚风险。
我们确定了 6 种抗生素的 9 项研究。环丙沙星是研究最多的药物。研究结果具有异质性,且普遍存在较高的偏倚风险。三项小型研究,两项关于环丙沙星,一项关于克拉霉素,比较了发热患者和临床康复患者的药代动力学,表明这些患者的生物利用度没有改变。其他研究要么比较了发热患者的药代动力学与健康志愿者早期研究中的报告药代动力学值(n=2),要么根本没有进行比较,结论不明确(n=4)。
对于非 ICU 住院感染全身感染初始阶段患者口服抗生素的生物利用度,目前存在明显的知识空白。需要设计良好的研究来阐明患者是否可以从更早的静脉-口服转换中获益。